Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients

Biomarkers of immune exhaustion were associated with how long a patient was able to control HIV after treatment was interrupted, according to a study presented at CROI 2015.

Published
11 hours ago
From
The Body
Pakistan: Factory making fake Hepatitis C drug raided

Assisted by the Federal Investigation Authority (FIA), personnel of the Drug Regulatory Authority of Pakistan (DRAP) raided one of the local industries in Islamabad’s Kahuta industrial area here Saturday, leading to the discovery of unlawful manufacturing of Sofasbuvir tablets, which are used for the treatment of Hepatitis C, and Everlong tablets, the registration of which has long been withdrawn.

Published
04 March 2015
From
The International News
Study of potential HIV 'cure' wins FDA nod

The trial at the City of Hope medical center will take blood-producing stem cells from patients infected with HIV and use a kind of molecular scissors — enzymes called zinc finger nucleases — to edit a protein that the virus uses to infect cells. The method was developed by Richmond's Sangamo BioSciences Inc.

Published
04 March 2015
From
San Francisco Business Times
HIV attachment inhibitor BMS-663068 safe and effective in phase 2b study

Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in

Published
04 March 2015
By
Liz Highleyman
Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3

The TEMPRANO study presented as a late breaker oral presentation, included important information for timing of TB prophylaxis and the timing of ART in TB-endemic countries. The conclusions though do not support universally starting treatment at CD4 counts >500 or answer the primary question of the international START study.

Published
03 March 2015
From
HIV i-Base
Doctor who cured ‘Berlin patient’ of HIV: ‘We knew we were doing something very special’

Dr. Gero Hütter and Timothy Ray Brown speak about the transplant that forever linked them in medical history.

Published
02 March 2015
From
Fred Hutch News
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Published
27 February 2015
By
Gus Cairns
Inflammation Persists Despite Very Early HIV Treatment

Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington.

Published
27 February 2015
From
The Body Pro
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil

Published
27 February 2015
By
Liz Highleyman
48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients. Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells. Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells PRINCETON, N.J., February 25, 2015--Bristol-Myers Squibb Company (NYSE:BMY) today announced data...

Published
26 February 2015
From
Bristol Myers Squibb press release
← First12345...381Next →

Filter by country